GSA Capital Partners LLP Invests $47,000 in VYNE Therapeutics Inc. $VYNE

GSA Capital Partners LLP purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, Holdings Channel reports. The fund purchased 71,533 shares of the company’s stock, valued at approximately $47,000. GSA Capital Partners LLP owned approximately 0.11% of VYNE Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in VYNE Therapeutics in the fourth quarter worth $46,000. Rangeley Capital LLC boosted its position in shares of VYNE Therapeutics by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after purchasing an additional 18,064 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of VYNE Therapeutics during the 3rd quarter worth $74,000. Geode Capital Management LLC grew its stake in shares of VYNE Therapeutics by 64.2% during the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock worth $131,000 after purchasing an additional 88,030 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of VYNE Therapeutics in the 4th quarter valued at about $147,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

VYNE Therapeutics Price Performance

VYNE opened at $28.32 on Wednesday. The stock has a market cap of $18.98 million, a P/E ratio of -74.54 and a beta of 2.00. The stock’s 50 day simple moving average is $31.94 and its 200 day simple moving average is $31.47. VYNE Therapeutics Inc. has a 1-year low of $14.03 and a 1-year high of $79.75.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

VYNE Therapeutics Announces Dividend

The company also recently declared a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were given a $19.00 dividend.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.